SECsense Logo

ADMA Biologics, Inc. 8-K Report: Key Insights on Recent Developments (Jan 13, 2025)

$ADMA
Form 8-K
Filed on: 2025-01-13
Source
ADMA Biologics, Inc. 8-K Report: Key Insights on Recent Developments (Jan 13, 2025)

Based on the provided section of the financial report in XBRL format, here are the key insights and information extracted:

  1. Company Information:
  • Company Name: ADMA Biologics, Inc.
  • CIK: 0001368514
  • Incorporation State: Delaware (DE)
  • SEC File Number: 001-36728
  • EIN: 56-2590442
  • Address: 465 State Route 17, Ramsey, NJ 07446
  • Phone Number: 201-478-5552
  1. Filing Type:
  • Form: 8-K (Current Report)
  • Filing Date: January 13, 2025
  1. Stock Information:
  • Stock Exchange: NASDAQ
  • Type of Stock: Common Stock
  1. Reporting Period:
  • Start Date: January 13, 2025
  • End Date: January 13, 2025
  1. Miscellaneous:
  • The report is structured in XBRL format, which is standard for SEC filings, allowing for easier data extraction and analysis.

Insights:

  • The filing indicates that ADMA Biologics, Inc. is reporting significant information on a specific date (January 13, 2025), which may suggest an important event or change in the company's operations or financial status that necessitated an 8-K filing.
  • As a current report, it is likely to contain timely information that could affect the stock price and investor decisions.
  • The inclusion of a CIK identifier confirms that this is an official SEC filing, ensuring credibility and compliance with regulatory standards.

Conclusion:

It is important to follow up on the specific details included in the 8-K report filed by ADMA Biologics, Inc. on January 13, 2025, as it could provide insights into recent developments, risk factors, or strategic changes relevant to investors and stakeholders.